

Best of ASCO® 2017 in Japan

a program licensed by the American Societty of Clinical Oncology, Inc.

プログラム

※本セミナーでとりあげる演題は、2017年6月2日～6月6日に開催される米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに * 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

7月8日（土曜日）

as of 2017/06/20

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00-10:10	Welcome & Introduction				
	岡本 勇九州大学 / Best of ASCO部会 副部会長				
10:10-10:40	頭頸部がん		6009	Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).	Robert Haddad
	横田 知哉 静岡県立静岡がんセンター	清田 尚臣 神戸大学医学部附属病院	6007	Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.	Vanita Noronha
			6006*	Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979).	Hu Liang
10:40-10:50	Discussion: Q&A				
10:50-11:20	Developmental Therapeutics		LBA2501	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.	David Hyman
	久保木 恭利 国立がん研究センター東病院	村上 晴泰 静岡県立静岡がんセンター	108*	Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.	Toshihiko Doi
			2505	Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.	Funda Meric-Bernstam
11:20-11:30	Discussion: Q&A				
11:30-12:05	血液がん		7500	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.	Ian Flinn
	横山 雅大 がん研究会有明病院	池田 宇次 静岡県立静岡がんセンター	7506	Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.	Michael Pfreundschuh
			7508	Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.	James Godfrey
12:05-12:15	Discussion: Q&A				
12:15-12:30	Break 15分				
12:30-13:30	【演者】 浜本 康夫 慶應義塾大学病院	【座長】 兵頭 一之介 筑波大学	ランチョンセミナー 胃がんの薬物療法の基礎知識 共催：日本イーライリリー株式会社		
13:30-13:45	Break 15分				
13:45-14:25	乳がん - Neoadjuvant / Adjuvant		LBA500	APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).	Gunter Von Minckwitz
	高野 利実 虎の門病院	澤木 正孝 愛知県がんセンター中央病院	504	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.	Nadia Harbeck
			506	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.	Rita Nanda
			1008	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.	Sylvia Adams
14:25-14:40	Discussion: Q&A				
14:40-15:10	乳がん - Metastatic		1000	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy	George Sledge
	鶴谷 純司 近畿大学	佐治 重衡 福島県立医科大学	1001	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18).	Richard Finn
			LBA4	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).	Mark Robson
15:10-15:20	Discussion: Q&A				
15:20-15:35	Break 15分				
15:35-16:20	【演者】 関 順彦 帝京大学	【座長】 南 博信 神戸大学医学部附属病院	スイーツセミナー 本邦における免疫チェックポイント阻害薬の位置づけ 共催：小野薬品工業株式会社 / ブリストル・マイヤーズ スクイブ株式会社		
16:20-16:35	Coffee Break 15分				
16:35-16:55	Sarcoma		11000*	Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas.	Sant P. Chawla
	内藤 陽一 国立がん研究センター東病院	小野澤 祐輔 静岡県立静岡がんセンター	11001*	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.	Mrinal M. Gounder
16:55-17:05	Discussion: Q&A				
17:05-17:45	肺がん		8500	Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIa (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).	Yi-Long Wu
	後藤 悌 国立がん研究センター中央病院	笠原 寿郎 金沢大学附属病院	9004	Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).	Jaafar Bennouna
			LBA9007	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.	Tony Mok
			LBA9008	Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.	Alice Shaw
17:45-18:00	Discussion: Q&A				

Best of ASCO® 2017 in Japan

a program licensed by the American Societty of Clinical Oncology, Inc.

7月9日（日曜日）

Time	講師		司会	ASCO演題		
7:30	開場			ID	Abstract Title	Author
8:00-8:45	【演者】 赤松 弘朗 和歌山県立医科大学	【座長】 後藤 功一 国立がん研究センター東病院	モーニングセミナー 肺癌診療ガイドラインの方向性：最新の知見を踏まえて 共催：MSD株式会社／大鵬薬品工業株式会社			
8:45-9:00	Break 15分					
9:00-9:35	免疫療法		9504	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.		Caroline Robert
	北野 滋久 国立がん研究センター中央病院	石塚 賢治 鹿児島大学	103	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).		Shannon Maude
			9000	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.		Julie Brahmer
9:35-9:45	Discussion: Q&A					
9:45-10:15	婦人科がん		5505	A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.		Daniela Matei
	温泉川 真由 がん研究会有明病院	勝俣 範之 日本医科大学武蔵小杉病院	5507	Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.		Michael Friedlander
			5503*	A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043).		Hiroyuki Nomura
10:15-10:25	Discussion: Q&A					
10:25-11:05	泌尿器がん		4501	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).		Dean Bajorin
	松原 伸晃 国立がん研究センター東病院	田畑 健一 北里大学	4507	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).		Robert Motzer
			LBA5003	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).		Nicholas James
			LBA3	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naïve prostate cancer.		Karim Fizazi
11:05-11:20	Discussion: Q&A					
11:20-11:40	Melanoma / Skin Cancers		9507	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.		Hussein Tawbi
	近藤 俊輔 国立がん研究センター中央病院	陳 勁松 がん研究会有明病院	9508	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).		Georgina Long
11:40-11:50	Discussion: Q&A					
11:50-12:05	Break 15分					
12:05-13:05	【演者】 里内 美弥子 兵庫県立がんセンター	【座長】 今村 文生 大阪国際がんセンター	ランチョンセミナー ALK陽性肺癌の未来 ～よりよい治療を目指して～ 共催：中外製薬株式会社			
13:05-13:20	Coffee Break 15分					
13:20-13:50	Patient and Survivor Care		10009	FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US food and Drug Administration.		Harpreet Singh
	浜本 康夫 慶應義塾大学病院	上田 弘樹 和歌山県立医科大学	LBA10004	SCORAD III: Randomised non-inferiority phase III trial of single dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC).		Peter Hoskin
			LBA2	Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.		Ethan Basch
13:50-14:00	Discussion: Q&A					
14:00-14:30	消化器がん - Gastrointestinal Cancer		3505	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).		Scott Kopetz
	谷口 浩也 愛知県がんセンター中央病院	廣中 秀一 千葉県がんセンター	LBA1	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.		Qian Shi
			4004*	Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.		Salah-Eddin Al-Batran
14:30-14:40	Discussion: Q&A					
14:40-15:00	消化器がん - Hepatobiliary / Pancreas		4001	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).		Ann-Lii Cheng
	上野 誠 神奈川県立がんセンター	森実 千種 国立がん研究センター中央病院	4006	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.		John Primrose
15:00-15:10	Discussion: Q&A					
15:10-15:20	Closing Remarks 山本 信之 和歌山県立医科大学 / Best of ASCO部会 部会長					